Introduction
Myasthenia gravis (MG) with anti-acetylcholine receptor (AChR) antibodies is characterized by muscle weakness and fatigability. The disease generally begins with ocular symptoms (ptosis and/or diplopia) and extends to other muscles in 80% of cases. It is a prototype autoimmune disease in which the target organ, the muscle, is distinct from the effector organ, the thymus. In MG patients with anti-AChR antibodies, functional and morphological abnormalities of the thymus are frequently observed. Patients can display a thymoma, especially after 50 years old, or B cell infiltrations associated with thymic hyperplasia of lymphoproliferative origin in younger patients and mainly women. 1 In contrast, no thymic abnormalities are observed in MG with muscle-specific kinase antibodies. In MG with LRP4 antibodies, thymic hyperplasia of lymphoproliferative origin has also been observed in a few patients but not further investigated so far. 2 Here, we mainly focus on thymic changes occurring in early-onset AChR + MG patients occurring usually before 45-50 year of age. Most of these MG patients present high level of anti-AChR antibodies and thymic follicular hyperplasia. Sex hormones may play a role in this form of the disease, as more than 80% of patients with follicular hyperplasia are women.
The normal thymus
The thymus is a primary lymphoid organ that provides a complex environment essential for T cell maturation and differentiation during their migration within the cortical and medullary thymic compartments. This is orchestrated via interactions between T cells and mainly thymic epithelial cells (TECs), but also other stromal cells, such as dendritic cells, fibroblasts, and myoid cells. 3, 4 In the cortex, in their first differentiation steps, immature T cells become progressively double positive for CD4 and CD8 coreceptors and acquire a complete T cell receptor (TCR). Further successful differentiation depends on the quality and the specificity of TCR interaction with major histocompatibility complex (MHC) on stromal cells. A large majority of thymocytes are eliminated because the TCR-MHC interaction is too weak (death by neglect), and only a few thymocytes successfully pass positive selection. In contrast, in the medulla, thymocytes are eliminated if TCR-MHC interactions are too strong (negative selection). This is the basis of the central tolerance process based on the ability of TECs to express a repertoire of tissue-specific antigens (TSAs) that are presented to T cells. The expression of these TSAs is monitored by the autoimmune regulator AIRE or the transcription factor FEZ family zinc finger 2. 5, 6 In this context, TECs are able to express the different AChR subunits whose expression is controlled by AIRE. 7, 8 Lately, AIRE expression has been demonstrated to be downregulated by estrogen, explaining the female predisposition to autoimmunity, including MG, as detailed in this special issue by BerrihAknin et al. 9 Thymic myoid cells that possess the antigenic characteristics of skeletal muscle cells also express all AChR subunits and display a functional AChR. 7, 10 TECs are also involved in the selective induction of natural regulatory T cells. 11 Medullary TECs promote the generation of regulatory T cells and favor their functionality. 12 Hassall's corpuscles are also observed in thymic medulla and are formed by concentrically arranged TECs that could correspond to highly differentiated TECs. Their precise function remains unclear. 13 Altogether, this highlights that the thymus is a complex organ indispensable to set immune central tolerance, and thymic dysfunction can lead to autoimmunity.
Thymic abnormalities in early-onset MG
Pathological alterations of the thymus are very often observed in AChR-MG patients with a generalized disease. Thymic hyperplasia of lymphoproliferative origin is observed in 50-60% of these patients, a thymoma is detected in approximately 15% of the patients, and, in the other cases, the thymus is atrophic or involuted with mainly adipose tissue and residual areas of thymic parenchyma. As described below, the hyperplastic thymus in MG displays numerous features normally observed in secondary lymphoid organs (SLOs) and, owing to its inflammatory status, the hyperplastic MG thymus is even considered a tertiary lymphoid organ (TLO).
Abnormal T cell functionality
In the thymus of MG patients, no obvious changes are observed concerning the frequency of CD4 + and CD8 + T cells that are exported to the periphery. 14 However, other changes have been demonstrated. Natural regulatory T cells that differentiate in the thymus are clearly less functional in the thymus of MG patients, and this is also observed to a lesser degree in regulatory T cells in the periphery. 15, 16 Later, it was demonstrated that the altered immune regulatory function observed for T cells in MG patients was not only linked to the functional defect of regulatory T cells. Indeed, effector T cells from the thymus of MG patients are also resistant to suppression by regulatory T cells, and this is probably due to the inflammatory thymic environment.
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Immunoregulatory defects are thus observed in both regulatory and effector T cells in MG patients. This is associated with changes in the expression of proinflammatory cytokines by MG T cells, such as an interleukin (IL)-17 signature in regulatory T cells and increases in interferon (IFN)-␥ , IL-21, and tumor necrosis factor ␣ expression in both regulatory and effector T cells. 17 These data suggest that the inflammatory milieu of the MG thymus alters the function and plasticity of CD4 + T cells, leading to impaired function of regulatory T cells and resistance of effector T cells to suppression.
Peripheral cell infiltrations leading to germinal center development B cells can be detected at low levels (around 0.1-0.5% of thymocytes) in normal thymuses, and they are located mainly in the medulla and perivascular spaces. 18 Their precise role is not clear, but medullary B cells could be involved in negative selection, while perivascular spaces contain mainly plasma cells that could confer protection against pathogens. 19, 20 One of the main features characterizing the thymus in AChR + MG is the presence of an increased number of B cells, often organized in germinal centers (GCs). GCs can sometimes be observed in normal thymuses, increasing with age, 21, 22 but this is particularly a characteristic of AChR + MG thymuses (Fig. 1A) . 23 The presence of thymic GCs in other autoimmune diseases has not been clearly established. There is a clear association between the thymic follicular development and the age and gender of the patients: (1) the youngest patients display the highest degree (with three or more GCs per thymic section) and the older patients display the lowest degree (with fewer than two GCs per thymic section) of follicular hyperplasia, and (2) 80% of patients with thymic hyperplasia are women. 1 Recently, an increased number of T follicular helper (T FH ) cells have also been described in the periphery and in the thymus of MG patients. 24 T FH cells are normally located in the GCs of SLOs, where they play a central role in B cell maturation and antibody production. The MG thymus contains all components to set an immune response as in SLOs and in particular an immune sensitization against AChR: (1) medullary TECs and myoid cells express AChR, 7, 10 (2) thymic B cells can produce antiAChR antibodies, 25, 26 and (3) anti-AChR autoreactive T cells are present. 27 The thymuses of AChR + patients have been shown to contain B cells producing anti-AChR antibodies, suggesting a possible expansion of specific B cells. 28, 29 However, the polyclonality of thymic B cells and an overall increased expression of immunoglobulin genes, independent of antigenic specificity, have been demonstrated in MG patients. [29] [30] [31] The clear implication of the thymus in MG is also demonstrated using immunodeficient mice that are grafted with thymic biopsies from MG patients. Indeed, almost all the animals display human anti-AChR Abs in their serum, and 50% of them develop MG-like symptoms in correlation with the loss of AChR at the muscle endplates. 32 
As described by Truffault et al., AChR
+ MG patients with thymic hyperplasia have higher antiAChR antibody titers than patients with thymoma or involuted thymuses, and a clear correlation exists between the degree of thymic hyperplasia and serum levels of anti-AChR antibodies. 1 Moreover, the number of GCs is reduced in patients undergoing corticosteroid treatment. 23 All of these observations support the role of the thymus in the pathogenesis of MG, and thymectomy is often advised for AChR + MG patients. A recent randomized trial in MG patients treated with prednisolone demonstrated the benefit of thymectomy in improving MG symptoms over a 3-year follow-up period. 33 
Neoangiogenic processes
The development of thymic hyperplasia is supported by active neoangiogenic processes with high endothelial venule (HEV) and lymphatic endothelial vessel (LEV) development. HEVs are found in SLOs and chronically inflamed tissues. They are specialized venules bearing on their luminal surface diverse chemokines and expressing high levels of peripheral node addressin carbohydrate, which allows the homing of lymphocytes and dendritic cells. 34 Using immunohistochemistry, only a few HEVs are detected in the thymus of non-MG adults. 35 In contrast, in the thymus of MG patients, increased numbers of HEVs are observed around GCs (Fig. 1B) , correlating with the degree of thymic hyperplasia. Such high numbers of HEVs in hyperplastic thymuses suggest that peripheral cells enter the MG thymus through these specialized vessels.
The number of thymic HEVs is reduced in patients undergoing corticosteroid treatment. 35 The increased expression of lymphatic markers, such as vascular endothelial growth factor receptor 3 and PROX1, has been demonstrated in hyperplastic thymuses, also suggesting the expansion of the lymphatic system. LEVs expressing specifically CCL21 have been described in hyperplastic MG thymuses, as detailed below (Fig. 1C) . 36 Lymphangiogenesis occurs throughout life in homeostasis and diseases. It has been described in lymph nodes after immunization, where it was shown to be dependent on the entry of B cells. 37 Efficient cell recruitment via HEVs or LEVs is a multistep process, and chemokines displayed on vessels are involved in the transmigration of circulating cells. 38 
Chemokine overexpression
Chemokines play a central role in thymopoïesis through their chemotactic and chemorepulsive properties, allowing for the recruitment of prothymocytes, the migration of thymocytes from the cortex to the medullary region, and their export to the periphery. Chemokines are also crucial for peripheral cell recruitment in SLOs. 39 A transcriptome study demonstrated that thymic chemokine expression profiles differ in MG patients in association with increased chemotactic properties of hyperplastic thymic extracts. 31 As described below, several chemokines are increased or abnormally expressed in the MG thymus, as detailed in Table 1 . 23, 31, 35, 36, [40] [41] [42] Altogether, these data show that chemokine profiles are strongly modified in the MG thymus. They are overexpressed in different cells and probably play a central role in peripheral cell recruitment in the MG thymus and the development of ectopic GCs.
Expression of CXCL12 and CCL17 by ectopic high endothelial venules. Under physiological conditions, diverse chemokines are displayed on HEVs in SLOs and are involved in the transmigration of circulating cells across HEVs. 38 The expression of several chemokines on thymic HEVs was investigated by Weiss et al. Chemokines investigated were known to be expressed by HEVs in SLOs or chronically inflamed tissues and also known to be dysregulated in the MG thymus at that time: CCL19, CCL21, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, and RANTES/CCL5. 35 Among these chemokines, only CXCL12 was found expressed on the lumen side of thymic HEVs. Moreover, antigen-presenting cells, such as monocytes/macrophages, dendritic cells, and B cells expressing CXCL12 receptor CXCR4, are detected inside and around thymic HEVs. CCL17 has also been described on thymic HEVs and could favor the recruitment of CCR4 + dendritic cells.
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Abnormal expression of CCL21 on LEVs. In the periphery, CCL21 is known to play a central role in immune surveillance and defense by controlling the circulation of T cells and dendritic cells within lymphoid and peripheral organs. CCL21 is also involved in naive B cell recruitment. 36 In the thymus, CCL21 and CCL19, both interacting with the receptor CCR7, play important roles in thymopoiesis. 43 In MG patients, thymic hyperplasia is specifically associated with the thymic overexpression of CCL21 and CCL19. The overexpression of CCL21 in hyperplastic MG thymuses is due to LEVs (Fig. 1C) . Thymic overexpression of CCL21 in MG could thus play a role in bringing naive B cells, but perhaps also peripheral dendritic cells and T cells, in contact with the inflammatory environment characteristic of MG thymus, where they can be sensitized against AChR.
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Overexpression of CXCL13 by thymic epithelial cells. CXCL13 is the most potent chemoattractant for B cells. CXCL13 interacts with cells through its receptor CXCR5, which is also expressed on T FH cells. In SLOs, CXCL13 participates in GC formation and it is also overexpressed at inflammatory sites characterized by ectopic GC development.
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CXCL13 mRNA is only expressed at very low levels in normal thymuses. However, in AChR + MG patients, thymic CXCL13 expression is strongly increased. Even if CXCL13 is known to be produced by GCs, medullary TECs in MG patients also expressed abnormal levels of CXCL13. 23 The active recruitment of peripheral B cells but also T FH cells via CXCL13 in MG thymuses could support the development of ectopic GCs.
Inflammation is mandatory to reveal properties of CXCL13. As CXCL13 is overexpressed by medullary TECs in MG patients, 23 transgenic mice overexpressing CXCL13 under the control of the keratin 5 (K5) promoter were developed. The objective was to mimic thymic overexpression of CXCL13 by medullary TECs as in the MG thymus. Data demonstrate that transgenic K5-Cxcl13 mice overexpress CXCL13 in their thymus, but this does not induce the recruitment of B cells. However, in inflammatory conditions induced by the injections of a molecule mimicking dsRNA from viral infection (polyinosinic-polycytidylic acid (poly(I:C)) or the immunization with a strong adjuvant, the recruitment of B cells is detected in the thymus. 46 The classical mouse model of MG is induced by immunizing animals with purified AChR extracted from the electric organ of torpedo fish (T-ACHR) together with complete Freund's adjuvant. If the animals produce antibodies that induce loss of AChR at the muscle endplate and dysfunction of the neuromuscular transmission, this model does not present thymic abnormalities. 47 Using the K5-Cxcl13 mice, it was demonstrated that mice are more susceptible to experimental autoimmune MG, with stronger clinical signs, higher titers of anti-AChR antibodies, increased thymic B cells, and the development of GC-like structures in the thymus. 46 Altogether, these data suggest that thymic inflammation is mandatory to reveal the chemotactic properties of CXCL13. Inflammation subsequent to pathogen infection appears to be a key event to optimize the recruitment of mature lymphocytes to peripheral organs and even the thymus. 48, 49 IFN-I that is released during pathogen infection could favor cell motility.
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Pathogen infection signature associated with Toll-like receptor expression Pathogens are major environmental factor candidates for driving/perpetuating autoimmunity. However, since autoimmunity onset can occur well after a possible triggering infection, when the pathogen might have been cleared or the antiviral immune responses might have subsided, it is difficult to link infections with autoimmune diseases.
Nevertheless, the presence of poliovirus-infected macrophages and Epstein-Barr virus (EBV)-infected B cells has been shown in MG thymus. 51, 52 In MG, striking evidence of chronic inflammation and emerging data on persistent viral infections in the thymus of MG patients strongly support the hypothesis that the innate immune system may promote, exacerbate, and/or maintain the autoimmune condition.
Toll-like receptors (TLRs) play major roles in innate immunity. TLRs 1-10 recognize specific microbial-derived molecular structures. 53 The expression levels of TLRs in the thymus of MG patients have been analyzed in different studies reviewed by Robinet et al. 54 Briefly, TLRs 1-9 are all expressed in control thymuses. In MG thymuses, the overexpression is described for TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9, and correlations between CD19 (a B cell marker) mRNA expression and TLR6, TLR8, and TLR9 mRNA expression have been demonstrated. 54 To investigate the potential consequences of pathogen infection on the thymus, the effects of TLR agonists have been analyzed in vitro in human cultured TECs and in vivo in mouse thymus. In human TECs, among all TLR agonists, poly(I:C), a synthetic analog of dsRNA mimicking viral infections, specifically induces the thymic overexpression of ␣-AChR, but not other AChR subunits or TSAs. This induction is mediated by the release of IFN-␤ and is completely inhibited by IFN-I receptor or IFN-␤ blocking antibodies. 55 In C57Bl/6 mice, injections of poly(I:C) for 1 week also trigger the specific thymic expression of ␣-AChR. Poly(I:C) injections also induce other thymic changes, such as the overexpression of IFN-I subtypes, CXCL13, and CCL21, associated with an increased recruitment of thymic B cells. All of these thymic changes disappear after 1 week, but prolonged poly(I:C) injections over 6-8 weeks induce the development of an anti-AChR response in the periphery, with the proliferation of autoreactive B cells against AChR in lymph nodes and the production of anti-AChR antibodies. The presence of circulating anti-AChR antibodies leads to MG symptoms with a loss of AChR on the muscle diaphragm and muscle weakness. 55 In accordance with these observations on poly(I:C) effects, dsRNA-signaling pathways are activated in MG thymuses. 55 This could be related to the thymic EBV signature observed in MG, as EBV encodes small RNAs that trigger TLR3 signaling and induce IFN-I and proinflammatory cytokine expression, similar to poly(I:C).
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Central role of interferon-␤
Inflammation constitutes an essential component of the innate immune response induced by pathogens that stimulate the release of proinflammatory molecules. IFN-Is are secreted by various cells as an antiviral defense mechanism and, depending on the context, can either be considered antiinflammatory, as in multiple sclerosis, or proinflammatory, as in systemic lupus erythematosus. [57] [58] [59] The implication of IFN-I in MG has long been suggested in various ways: (1) clinical reports demonstrate the development of MG after IFN-␣ or IFN-␤ therapies, 60 (2) antibodies against IFN-␣ are found in some MG patients, mainly those with thymoma, 61 and (3) IFN-␤ is overexpressed in MG thymuses together with numerous IFN-I-induced genes, as detailed by Poea-Guyon et al. 55, 62, 63 IFN-I proteins, specifically IFN-␤, induce the specific expression of ␣-AChR by TECs and not that of other TSAs. It also increases TEC death and the uptake by dendritic cells of TEC proteins, potentially the ␣-AChR that is overexpressed in IFN-␤-treated TECs. In parallel, IFN-␤ triggers the expression of CXCL13 and CCL21 by TECs and lymphatic endothelial cells, respectively, and consequently could favor peripheral cell recruitment in the thymus. IFN-␤ also induces the expression of B cell activating factor (BAFF), which favors B cell survival and is overexpressed by TECs in MG thymus. 64 Similar changes are observed in vivo, as the injections of poly(I:C) to C57BL/6 mice trigger a thymic overexpression of IFN-␤ and IFN-␣2 associated with increased expressions of CXCL13, CCL21, and BAFF and favor the recruitment of B cells. These changes are not observed in the thymus of IFN-I receptor gene knockout mice injected with poly(I:C). 64 Altogether, these observations demonstrate that IFN-␤ orchestrates thymic events that could lead to MG by triggering the overexpression of ␣-AChR, probably inducing thymic dendritic cell autosensitization, the abnormal recruitment of peripheral cells, and GC formation. All of these observations are summarized in Figure 2 . It was also demonstrated that IFN-I subtypes might play central roles in thymoma-associated MG. Huge increases of IFN-I subtypes are observed in thymoma-associated MG, but not in thymomas without MG or in control thymuses. These results reinforce a specific role of IFN-I in the anti-AChR response associated with MG. 65 In MG patients, the fact that IFN-␤ is overexpressed even long after disease onset suggests a persistent induction owing to the presence of a pathogenic agent, as discussed above with EBV, or an altered retrocontrol mechanism to repress IFN-I signaling that could affect downregulation of IFN-I receptor from the cell surface, dephosphorylation of signaling components of the IFN-I pathway, induction of negative regulators, and induction of microRNAs (miRNAs).
Dysregulated expression of miRNAs
MiRNAs are small RNAs that are posttranscriptional regulators of gene expression. They interact specifically with mRNAs, leading to their degradation or to the inhibition of their translation and consequently decreasing protein expression. Recent studies have investigated and identified circulating miRNAs as readily accessible blood biomarkers for MG patients. [66] [67] [68] The differential expression of some miRNAs is also observed in peripheral blood mononuclear cells from MG patients. 69, 70 As miRNAs play an important role in the regulation of inflammation and autoimmunity, we can envisage that altered miRNA expression could be involved in thymic changes associated with MG. Besides, as miRNAs are known to be expressed in the thymus and exported in exosomes to improve cellular communications, 71 it would be interesting to investigate the modifications of thymic miRNA expression in a myasthenic context. Environmental factors, such as infections, are able to modify the expression of specific miRNAs and eventually alter thymic function. 72 Moreover, miR-29a is an important regulator of the IFN-I signaling pathway, targeting IFN-I receptor in TECs and reducing cell sensitivity to IFN-I and consequently pathogen infections. 73 MiR-205 has also been demonstrated to be important in maintaining thymopoiesis upon inflammatory perturbations. 74 All of these studies highlight the role of miRNAs in thymus homeostasis in mice and suggest that altered miRNA expression in the human thymus could be observed in MG patients.
Conclusions
Chronically inflamed tissues can turn into TLOs that possess numerous specific characteristics of SLOs, such as the development of a vascular system, the infiltration of leukocytes, and the presence of GCs, sustained by the overexpression of chemokines and inflammatory cytokines. The hyperplastic MG thymus displays all the characteristics of TLOs. Recent data suggest that IFN-␤ could initiate and orchestrate these thymic changes and the intrathymic autoimmune response to AChR. Future investigations are needed to decipher the upstream events, what is triggering thymic inflammation, and why this inflammation is sustained over time.
